CXCR3 and glioblastoma: From a translational perspective, phase I and II clinical trials of dendritic cell vaccines (polyinosinic-polycytidylic acid and carboxymethylcellulose (poly-ICLC) boosted αDC1) have shown promise for reducing GBM recurrence through a CXCR3-dependent mechanism.